BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24893616)

  • 41. Multiplex fluorescence in situ hybridization in identifying chromosome involvement of complex karyotypes in de novo myelodysplastic syndromes and acute myeloid leukemia.
    Xu W; Li JY; Liu Q; Zhu Y; Pan JL; Qiu HR; Xue YQ
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e86-95. PubMed ID: 20089000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistent malignant stem cells in del(5q) myelodysplasia in remission.
    Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundström I; Strömbeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Rydén T; Vyas P; Göhring G; Schlegelberger B; Johansson B; Hellström-Lindberg E; List A; Nilsson L; Jacobsen SE
    N Engl J Med; 2010 Sep; 363(11):1025-37. PubMed ID: 20825315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Ureshino H; Kizuka H; Kusaba K; Sano H; Nishioka A; Shindo T; Kubota Y; Ando T; Kojima K; Kimura S
    Int J Hematol; 2017 May; 105(5):692-696. PubMed ID: 27914067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
    Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
    Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.
    Giagounidis AA; Germing U; Haase S; Hildebrandt B; Schlegelberger B; Schoch C; Wilkens L; Heinsch M; Willems H; Aivado M; Aul C
    Leukemia; 2004 Jan; 18(1):113-9. PubMed ID: 14586479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
    Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome.
    Hoffman MW; Janney S; Batanian JR
    Cancer Genet Cytogenet; 2009 Jun; 191(2):106-8. PubMed ID: 19446747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
    Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
    Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.
    Westbrook CA; Hsu WT; Chyna B; Litvak D; Raza A; Horrigan SK
    Br J Haematol; 2000 Sep; 110(4):847-55. PubMed ID: 11054067
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities.
    Andreasson P; Johansson B; Arheden K; Billström R; Mitelman F; Höglund M
    Genes Chromosomes Cancer; 1997 Jun; 19(2):77-83. PubMed ID: 9171997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
    Baldazzi C; Luatti S; Zuffa E; Papayannidis C; Ottaviani E; Marzocchi G; Ameli G; Bardi MA; Bonaldi L; Paolini R; Gurrieri C; Rigolin GM; Cuneo A; Martinelli G; Cavo M; Testoni N
    Genes Chromosomes Cancer; 2016 Apr; 55(4):375-88. PubMed ID: 26815134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
    Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
    Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.